Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer
Predicting response to systemic treatments in breast cancer (BC) patients is an urgent, yet still unattained health aim. Easily detectable molecules such as long non-coding RNAs (lncRNAs) are the ideal biomarkers when they act as master regulators of many resistance mechanisms, or of mechanisms that...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/9/2711 |
id |
doaj-47835a181ef2468fbcf4ad50371cdd24 |
---|---|
record_format |
Article |
spelling |
doaj-47835a181ef2468fbcf4ad50371cdd242020-11-24T22:23:22ZengMDPI AGInternational Journal of Molecular Sciences1422-00672018-09-01199271110.3390/ijms19092711ijms19092711Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast CancerAlma D. Campos-Parra0Eduardo López-Urrutia1Luz Tonantzin Orozco Moreno2César López-Camarillo3Thuluz Meza-Menchaca4Gabriela Figueroa González5Lilia P. Bustamante Montes6Carlos Pérez-Plasencia7Laboratorio de Genómica, Instituto Nacional de Cancerología (INCan), Av. San Fernando 22, Col. Sección XVI, Tlalpan, C.P. 14080 Ciudad de México, MexicoUnidad de Biomedicina, FES-IZTACALA, Universidad Nacional Autónoma de México (UNAM), Av. De Los Barrios 1. Col. Los Reyes Iztacala, C.P. 54090 Tlalnepantla, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología (INCan), Av. San Fernando 22, Col. Sección XVI, Tlalpan, C.P. 14080 Ciudad de México, MexicoPosgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, San Lorenzo 290, Del Valle Sur, Benito Juárez, C.P. 03100 Ciudad de México, MexicoLaboratorio de Genómica Humana, Facultad de Medicina, Universidad Veracruzana (UV), Médicos, Unidad del Bosque, Xalapa, C.P. 91010 Veracruz, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología (INCan), Av. San Fernando 22, Col. Sección XVI, Tlalpan, C.P. 14080 Ciudad de México, MexicoDecanato. Ciencias de la salud. Universidad Autónoma de Guadalajara. Av. Patria 1201, Col. Lomas del Valle, C.P. 45129 Zapopan, MexicoLaboratorio de Genómica, Instituto Nacional de Cancerología (INCan), Av. San Fernando 22, Col. Sección XVI, Tlalpan, C.P. 14080 Ciudad de México, MexicoPredicting response to systemic treatments in breast cancer (BC) patients is an urgent, yet still unattained health aim. Easily detectable molecules such as long non-coding RNAs (lncRNAs) are the ideal biomarkers when they act as master regulators of many resistance mechanisms, or of mechanisms that are common to more than one treatment. These kinds of markers are pivotal in quasi-personalized treatment selection, and consequently, in improvement of outcome prediction. In order to provide a better approach to understanding development of disease and resistance to treatments, we reviewed current literature searching for lncRNA-associated systemic BC treatments including endocrine therapies, aromatase inhibitors, selective estrogen receptor modulators (SERMs), trastuzumab, paclitaxel, docetaxel, 5-fluorouracil (5-FU), anthracyclines, and cisplatin. We found that the engagement of lncRNAs in resistance is well described, and that lncRNAs such as urotelial carcinoma-associated 1 (UCA1) and regulator of reprogramming (ROR) are indeed involved in multiple resistance mechanisms, which offers tantalizing perspectives for wide usage of lncRNAs as treatment resistance biomarkers. Thus, we propose this work as the foundation for a wide landscape of functions and mechanisms that link more lncRNAs to resistance to current and new treatments in years of research to come.http://www.mdpi.com/1422-0067/19/9/2711breast cancerlncRNAssystemic treatments |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alma D. Campos-Parra Eduardo López-Urrutia Luz Tonantzin Orozco Moreno César López-Camarillo Thuluz Meza-Menchaca Gabriela Figueroa González Lilia P. Bustamante Montes Carlos Pérez-Plasencia |
spellingShingle |
Alma D. Campos-Parra Eduardo López-Urrutia Luz Tonantzin Orozco Moreno César López-Camarillo Thuluz Meza-Menchaca Gabriela Figueroa González Lilia P. Bustamante Montes Carlos Pérez-Plasencia Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer International Journal of Molecular Sciences breast cancer lncRNAs systemic treatments |
author_facet |
Alma D. Campos-Parra Eduardo López-Urrutia Luz Tonantzin Orozco Moreno César López-Camarillo Thuluz Meza-Menchaca Gabriela Figueroa González Lilia P. Bustamante Montes Carlos Pérez-Plasencia |
author_sort |
Alma D. Campos-Parra |
title |
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer |
title_short |
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer |
title_full |
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer |
title_fullStr |
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer |
title_full_unstemmed |
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer |
title_sort |
long non-coding rnas as new master regulators of resistance to systemic treatments in breast cancer |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2018-09-01 |
description |
Predicting response to systemic treatments in breast cancer (BC) patients is an urgent, yet still unattained health aim. Easily detectable molecules such as long non-coding RNAs (lncRNAs) are the ideal biomarkers when they act as master regulators of many resistance mechanisms, or of mechanisms that are common to more than one treatment. These kinds of markers are pivotal in quasi-personalized treatment selection, and consequently, in improvement of outcome prediction. In order to provide a better approach to understanding development of disease and resistance to treatments, we reviewed current literature searching for lncRNA-associated systemic BC treatments including endocrine therapies, aromatase inhibitors, selective estrogen receptor modulators (SERMs), trastuzumab, paclitaxel, docetaxel, 5-fluorouracil (5-FU), anthracyclines, and cisplatin. We found that the engagement of lncRNAs in resistance is well described, and that lncRNAs such as urotelial carcinoma-associated 1 (UCA1) and regulator of reprogramming (ROR) are indeed involved in multiple resistance mechanisms, which offers tantalizing perspectives for wide usage of lncRNAs as treatment resistance biomarkers. Thus, we propose this work as the foundation for a wide landscape of functions and mechanisms that link more lncRNAs to resistance to current and new treatments in years of research to come. |
topic |
breast cancer lncRNAs systemic treatments |
url |
http://www.mdpi.com/1422-0067/19/9/2711 |
work_keys_str_mv |
AT almadcamposparra longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer AT eduardolopezurrutia longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer AT luztonantzinorozcomoreno longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer AT cesarlopezcamarillo longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer AT thuluzmezamenchaca longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer AT gabrielafigueroagonzalez longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer AT liliapbustamantemontes longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer AT carlosperezplasencia longnoncodingrnasasnewmasterregulatorsofresistancetosystemictreatmentsinbreastcancer |
_version_ |
1725764667751530496 |